Seroatlas · Human Serome Atlas

ZFYVE21

Zinc finger FYVE domain-containing protein 21

Also known as: MGC2550, ZF21, ZFY21_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9BQ24
Gene: ZFYVE21
Ensembl: ENSG00000100711
Chromosome: 14
Canonical length: 234 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable zinc ion binding activity. Predicted to be located in endosome and focal adhesion. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

234 residues, UniProt reviewed canonical sequence.

>Q9BQ24|ZFYVE21
     1  MSSEVSARRD AKKLVRSPSG LRMVPEHRAF GSPFGLEEPQ WVPDKECRRC MQCDAKFDFL
    61  TRKHHCRRCG KCFCDRCCSQ KVPLRRMCFV DPVRQCAECA LVSLKEAEFY DKQLKVLLSG
   121  ATFLVTFGNS EKPETMTCRL SNNQRYLFLD GDSHYEIEIV HISTVQILTE GFPPGGGNAR
   181  ATGMFLQYTV PGTEGVTQLK LTVVEDVTVG RRQAVAWLVA MHKAAKLLYE SRDQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ZFYVE21 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.31
Highest tissue expression: 96 nTPM

Expression across tissuesHPA

Tissue

choroid plexus: 96 nTPM
cerebral cortex: 95 nTPM
blood vessel: 91 nTPM
midbrain: 81 nTPM
amygdala: 79 nTPM
basal ganglia: 78 nTPM

Single-cell type

esophageal apical cells: 321 nCPM
oocytes: 193 nCPM
esophageal suprabasal cells: 183 nCPM
smooth muscle cells: 165 nCPM
peritubular myoid cells: 164 nCPM
megakaryocytes: 148 nCPM

Immune cell

intermediate monocyte: 58 nTPM
non-classical monocyte: 48 nTPM
eosinophil: 42 nTPM
classical monocyte: 36 nTPM
neutrophil: 30 nTPM
basophil: 29 nTPM

Brain region

white matter: 60 nTPM
spinal cord: 54 nTPM
medulla oblongata: 48 nTPM
basal ganglia: 47 nTPM
thalamus: 46 nTPM
amygdala: 39 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.59
gnomAD pLI: 0.34
gnomAD missense Z: 0.42
DepMap mean gene effect: 0.06
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

zinc ion binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

FYVE zinc finger
Zinc finger, FYVE/PHD-type
Zinc finger, RING/FYVE/PHD-type
Zinc finger, FYVE-related
FYVE zinc finger
Zinc finger FYVE domain-containing protein 21, C-terminal
Zinc finger FYVE 21, C-terminal domain superfamily
FYVE-type Zinc Finger Domain-Containing Protein
Zinc finger FYVE domain-containing protein 21 C-terminus

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ZFYVE21 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

PTK2

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ZFYVE21 as an antibody target. Whether an autoantibody or antibody against ZFYVE21 could matter depends on whether native ZFYVE21 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ZFYVE21 is annotated at the cell surface, where native ZFYVE21 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label ZFYVE21 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...